Searching Differential Expression Gene In Prostate Cancer Cell Lines Using Microarray And Analysis Of Gene Function

The vast amount of information available through the human genome project .However, the mere sequence information of the whole genome does not answer all our questions. What is required at this stage is a complete understanding of the function of genes and other parts of the genome so as to uncover how sets of genes and their products work together in normal and diseased conditions. DNA microarrays are some of the most powerful and versatile tools available, and there are several applications of microarray technology in cancer biology. Since cancer is a genetic disease arising from the progressive accumulation of many genetic alternations, identification of differences in the expression profile of tumor cells in comparison to their normal counterpart would provide a better platform for understanding the process of tumor formation and development.Prostate cancer is a leading cause of cancer-related deaths and the most commonly diagnosed cancer in men in the west. By nature, cancer in the prostate progresses slowly and can be treated effectively when detected early; however, the metastastatic disease presents a major challenge to improve survival rate and treatment efficacy. To overcome this problem, it is critical to identify predictors to distinguish prostate cancers that will progress and metastasize, and to separate them from those that will not progress during the expected lifetime of the patient. Metastatic prostate cancer proceeds through a series of distinct states such as transformation of normal prostatic epithelial cells to preinvasive primary tumor, androgen-dependent invasive cancer, and androgen-independent (AI) metastatic disease. These stages of prostate cancer involve multiple molecular changes some of which can be implicated to alterations in gene expression.Progression to androgen independence (AI) leading to uncontrolled cell growth is the main cause of death in prostate cancer. While almost all patients with metastatic prostate cancer will initially respond to anti-androgen treatments, the majority will fail hormonal treatments in less than 2 years. Both genetic and epigenetic alterations in...